trending Market Intelligence /marketintelligence/en/news-insights/trending/c1YCgV7OJmaBep7wSpOG7Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Report: AstraZeneca's lung cancer drug greenlit in China

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Report: AstraZeneca's lung cancer drug greenlit in China

AstraZeneca PLC received approval from China's Food and Drug Administration to market its new lung cancer drug Tagrisso in the country, Bloomberg News reported, citing the company's announcement on its WeChat account.

The approval comes as the Chinese regulator vowed to hasten drug approvals, and is considering simplifying requirements for international clinical trials.

Representatives from the drugmaker couldn't immediately be reached for comment, according to the report.